Trial Outcomes & Findings for Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study (NCT NCT02537951)

NCT ID: NCT02537951

Last Updated: 2019-06-11

Results Overview

AFI-intensity (delta F/F) at the 3rd fingertip, directly after application of grading nociceptive stimuli

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

Day 1, T=0h (AFI measurements), Day 1, T=6h (AFI measurements after lidocaine/prilocaine), Day 7 (AFI measurements after capsaicin)

Results posted on

2019-06-11

Participant Flow

all 10 healthy volunteers underwent 3 experiments, all 10 have completed these experiments: 1. AFI intensity measurements 2. lidocaine/prilocaine creme, one hour later followed by AFI intensity measurements 3. capsaicin patch (2 hours after lidocaine/prilocaine creme), one week later followed by AFI intensity measurements

Participant milestones

Participant milestones
Measure
10 Healthy Volunteers
10 healthy volunteers underwent three procedures, always in the same order: 1. baseline AFI measurements 2. application of lidocaine/prilocaine creme, 1 hour later followed by AFI measurements 3. application of capsaicin patches, 1 week later followed by AFI measurements
Overall Study
STARTED
10
Overall Study
COMPLETED
10
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
AFI Intensity in Healthy Volunteers
n=10 Participants
10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope AFI microscope: measurement of AFI intensities following increasing nociceptive stimulus intensities After AFI intensity measurements, the same experiment will be repeated one hour after application of lidocaine/prilocaine creme After the negative control experiment using lidocaine/prilocaine creme, AFI intensity measurements will be repeated one week after application of a capsaicin 8% patch (second negative control experiment)
Age, Continuous
25 years
n=10 Participants
Sex: Female, Male
Female
0 Participants
n=10 Participants
Sex: Female, Male
Male
10 Participants
n=10 Participants
Region of Enrollment
Netherlands
10 Participants
n=10 Participants

PRIMARY outcome

Timeframe: Day 1, T=0h (AFI measurements), Day 1, T=6h (AFI measurements after lidocaine/prilocaine), Day 7 (AFI measurements after capsaicin)

AFI-intensity (delta F/F) at the 3rd fingertip, directly after application of grading nociceptive stimuli

Outcome measures

Outcome measures
Measure
AFI Intensity in Healthy Volunteers
n=10 Participants
10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope AFI microscope: measurement of AFI intensities following increasing nociceptive stimulus intensities
Negative Control 1: Lidocaine/Prilocaine
n=10 Participants
10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1) negative control 1: lidocaine/prilocaine: measurement of AFI intensities following lidocaine/prilocaine cream
Negative Control 2: 8% Capsaicin
n=10 Participants
-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2) negative control 2: 8% capsaicin: measurement of AFI intensities following 8% capsaicin patch
AFI-intensity After Nociceptive Stimulation
0.60 unitless
Standard Error 0.25
0.25 unitless
Standard Error 0.25
0.50 unitless
Standard Error 0.50

Adverse Events

AFI Intensity in Healthy Volunteers

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Negative Control 1: Lidocaine/Prilocaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Negative Control 2: 8% Capsaicin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Joost L.M. Jongen

Erasmus MC

Phone: +31107041415

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place